Navigation Links
InterMune Reports Fourth Quarter And Full Year 2012 Financial Results And Business Highlights
Date:2/21/2013

ures before complete patient access to Esbriet is achieved.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company anticipates launches in the remaining three MSC of Netherlands, Finland and Ireland by mid-2013, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories was completed in January 2013.  ASCEND is a double-blind, placebo-controlled trial of 52 weeks duration with a primary endpoint of change in forced vital capacity (FVC) between baseline and Week 52.  The trial enrolled IPF patients with mild-to-moderate impairment in lung function and certain characteristics that the company believes enhance the probability of a successful study outcome.  Top-line results are expected in Q2 of 2014.
  • On January 22, 2013, InterMune completed a public offering of 15,525,000 shares of its common stock, including the underwriters' over-allotment, with net proceeds to the company of $145.7 million (after payment of underwriting discounts and commissions, and expenses).  InterMune also completed a concurrent public offering of $120.75 million aggregate principal amount of the company's 2.50% convertible Senior Notes due 2017, including the Note underwriters' over-allotment, with net proceeds to the company of $116.7 million (after payment of the underwriting discounts and commissions, and expenses).  The company has used proceeds from the convertible notes offering to repurchase and cancel $66.6 million of its outstanding $85.0 million aggregate principal amount 2015 Notes, and intends to repurchase the remaining $18.4 million of the outstanding 2015 Notes over time.
  • On February 14, 2013 InterMune announced that Sean P. Nolan has joined the company as Executive Vice President and Chief B
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
    2. InterMune to Present at J. P. Morgan Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune To Present At JMP Securities Healthcare Conference
    5. InterMune To Release Third Quarter Financial Results On November 7
    6. InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
    7. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    8. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    9. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    10. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    11. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)... Denville, NJ (PRWEB) January 22, 2015 ... shearing technologies such as the Bioruptor® and complete ... semi-automation system for chromatin immunoprecipitation, alleviating the need ... reagents and controls needed for ChIP of histones ...
    (Date:1/22/2015)... 22, 2015   GenoSpace , a precision medicine software company ... the broad use of genomic, imaging and other biomedical data ... Michelle Munson , CEO of Aspera, an IBM Company, ... - http://photos.prnewswire.com/prnh/20150122/170713 "We are pleased ...
    (Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
    (Date:12/24/2014)... Louis, Missouri (PRWEB) December 23, 2014 GMO ... biotechnology company, Syngenta, are in the process of being consolidated ... case is In Re: Syngenta AG MIR 162 Corn Litigation, ... District of Kansas. , Management of the Syngenta GMO corn ...
    Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
    ... Manufacturer is Pillar of Support for National Children,s ... Chopra CEO and Chief,Scientific Officer of Tishcon Corp ... the health of low income children in,America. In ... Tishcon,s,President, Vipin Patel, and Vice President, Arun Chopra, ...
    ... Israel, October 15 ,Simbionix USA Corporation is pleased ... of growth capital financing led by River Cities ... and other existing,shareholders, as well as Western Reserve ... investment will enable Simbionix to,accelerate the already rapid ...
    ... Inc.,(Nasdaq: SUPG ), a pharmaceutical company dedicated ... today announced the company,s plans,to present five posters ... Cancer Therapeutics" on October 23 and 24, 2008., ... advances,in the following compounds: MP-470, SGI-1776 and SGI-1252. ...
    Cached Biology Technology:Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 2Tishcon Corp Reaches Donation Milestone Exceeds 1 Million Bottles of Multi-Vitamins for Nourish America 3Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 2Simbionix Raises Largest Amount in Company's History in Venture Capital to Accelerate Growth 3SuperGen to Present Data at EORTC-NCI-AACR 2
    (Date:1/22/2015)... NEW YORK and POINT ROBERTS, Washington ... global news source covering leading sectors including technology and tech ... Personal Privacy marketplace featuring master pickpocket and security consultant ... wallet is stolen and talks about the Wocket™ biometric smart ...
    (Date:1/22/2015)... Jan. 22, 2015 Research and Markets ... the "Global Wearable Technologies Market and Applications, ... Trends and Forecast 2014-2020" report to their ... smart devices that can be worn on the ...
    (Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its launch in ... of people to eliminate the pain of trying to remember ... their own biometrics fused to their smartphones. To assist people ... Labs , the company that created 1U and focuses on ...
    Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3
    ... obesity among low-income infants should focus not only on what ... feeding practices, according to a study to be presented Saturday, ... in Boston. Adding cereal to bottles is one unhealthy ... because it may lead to overfeeding and excess weight gain ...
    ... Avocado, a significant fruit crop grown in many ... by Phytophthora root rot (PRR), a disease that has ... Latin America and crippled production in Australia and South ... to cost avocado growers approximately $30-40 million a year ...
    ... Germany, April 27th, 2012 - Genomatix is proud to ... in the biotech category at Hannover Messe, the world,s ... 14 categories to companies for products of a high ... are chosen by a panel of 30 experts including ...
    Cached Biology News:Low-income moms under stress may overfeed infants 2New avocado rootstocks are high-performing and disease-tolerant 2New avocado rootstocks are high-performing and disease-tolerant 3
    BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
    ... initiates apoptosis in mammalian cells. The ... a simple and convenient means for detecting ... intact cells. The assay utilizes a ... to rhodamine 110 (D2R), a reported substrate ...
    ...
    The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
    Biology Products: